Stop imatinib or dasatinib study in CP-CML patients mainitaining complete molecular response for two years
Not Applicable
Recruiting
- Conditions
- chronic phase chronic myeloid leukemia
- Registration Number
- JPRN-UMIN000007944
- Lead Sponsor
- Tokyo Women's Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1 Active primary double cancers 2 Pregnant or breast-feeding women 3 Patients who are not considered apropriate candicdates for this clinical trial by the investigators, because of past history of diseases, co-morbidities, or other reasons.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rate of CMR at 12 months after cessation of imatinib or dasatinib.
- Secondary Outcome Measures
Name Time Method